Cargando…

In Silico Identification and Evaluation of Leads for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease Using Complex Based Pharmacophore Mapping and Virtual Screening

Hepatitis C virus (HCV) infection is an alarming and growing threat to public health. The present treatment gives limited efficacy and is poorly tolerated, recommending the urgent medical demand for novel therapeutics. NS3/4A protease is a significant emerging target for the treatment of HCV infecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wadood, Abdul, Riaz, Muhammad, Uddin, Reaz, ul-Haq, Zaheer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923879/ https://www.ncbi.nlm.nih.gov/pubmed/24551230 http://dx.doi.org/10.1371/journal.pone.0089109

Ejemplares similares

A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach
por: Riaz, Muhammad, et al.
Publicado: (2023)

Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease
por: Wadood, Abdul, et al.
Publicado: (2013)

Targeting Dengue Virus NS-3 Helicase by Ligand based Pharmacophore Modeling and Structure based Virtual Screening
por: Halim, Sobia A., et al.
Publicado: (2017)

Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors
por: Uddin, Reaz, et al.
Publicado: (2022)

Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection
por: Pathak, Nikhil, et al.
Publicado: (2017)

Zika Virus NS3 Protease Pharmacophore Anchor Model and Drug Discovery
por: Pathak, Nikhil, et al.
Publicado: (2020)

An in-silico evaluation of COVID-19 main protease with clinically approved drugs
por: Tachoua, Wafa, et al.
Publicado: (2020)

Molecular docking analysis of fluoroquinolones and other natural and synthetic compounds with the HCV NS3 helicase
por: Ul Haq, Ahtesham, et al.
Publicado: (2022)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

Molecular screening of phytochemicals from Amelanchier Alnifolia against HCV NS3 protease/helicase using computational docking techniques
por: Khan, Mahim, et al.
Publicado: (2013)

Hepatitis C Viral NS3-4A Protease Activity Is Enhanced by the NS3 Helicase
por: Beran, Rudolf K. F., et al.
Publicado: (2008)

A combined 3D-QSAR and docking studies for the In-silico prediction of HIV-protease inhibitors
por: Ul-Haq, Zaheer, et al.
Publicado: (2013)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
por: Soumana, Djadé I., et al.
Publicado: (2014)

Identification of NS2B-NS3 Protease Inhibitors for Therapeutic Application in ZIKV Infection: A Pharmacophore-Based High-Throughput Virtual Screening and MD Simulations Approaches
por: Rehman, Hafiz Muzzammel, et al.
Publicado: (2023)

Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships
por: Hu, Katherine, et al.
Publicado: (2020)

Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener
por: B, Uma Reddy, et al.
Publicado: (2020)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

Engineered Toxins “Zymoxins” Are Activated by the HCV NS3 Protease by Removal of an Inhibitory Protein Domain
por: Shapira, Assaf, et al.
Publicado: (2011)

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics
por: Oerlemans, Rick, et al.
Publicado: (2020)

In Silico Screening, Alanine Mutation, and DFT Approaches for Identification of NS2B/NS3 Protease Inhibitors
por: Balajee, R., et al.
Publicado: (2016)

In silico testing of flavonoids as potential inhibitors of protease and helicase domains of dengue and Zika viruses
por: Cruz-Arreola, Omar, et al.
Publicado: (2022)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

Lead expansion and virtual screening of Indinavir derivate HIV-1 protease inhibitors using pharmacophoric - shape similarity scoring function
por: Shityakov, Sergey, et al.
Publicado: (2010)

Dengue virus serotypic replacement of NS3 protease or helicase domain causes chimeric viral attenuation but can be recovered by a compensated mutation at helicase domain or NS2B, respectively
por: Teramoto, Tadahisa
Publicado: (2023)

Allosteric Inhibitors of Zika Virus NS2B-NS3 Protease Targeting Protease in “Super-Open” Conformation
por: Meewan, Ittipat, et al.
Publicado: (2023)

Identification of Novel HIV 1- Protease Inhibitors: Application of Ligand and Structure Based Pharmacophore Mapping and Virtual Screening
por: Yadav, Divya, et al.
Publicado: (2012)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy
por: Dietz, Julia, et al.
Publicado: (2016)

The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)
por: Meanwell, Nicholas A., et al.
Publicado: (2018)

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease
por: Khan, Mahim, et al.
Publicado: (2022)

The New High Resolution Crystal Structure of NS2B-NS3 Protease of Zika Virus
por: Badshah, Syed Lal, et al.
Publicado: (2017)

1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease
por: Omar, Abdelsattar M., et al.
Publicado: (2020)

Evaluating Known Zika Virus NS2B-NS3 Protease Inhibitor Scaffolds via In Silico Screening and Biochemical Assays
por: Santos, Lucianna H., et al.
Publicado: (2023)

Pharmacophore based virtual screening for natural product database revealed possible inhibitors for SARS-COV-2 main protease
por: El-Ashrey, Mohamed K., et al.
Publicado: (2022)

HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptor
por: Sakata, Kotaro, et al.
Publicado: (2013)

Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity
por: Jittavisutthikul, Surasak, et al.
Publicado: (2016)

Treatment of HCV NS3/4a Protease Inhibitor Experienced Patients with Sofosbuvir Containing Regimens in an Outpatient Clinic
por: Gilroy, Shelley, et al.
Publicado: (2017)

Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients
por: Khan, Hafeez Ullah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_77a8u79hu223gv5ssusmmsn7gf